Reviewer's report

Title: Dynamics of cinacalcet use and biochemical control in hemodialysis patients: A Retrospective New-User Cohort Design

Version: 1 Date: 5 July 2015

Reviewer: Cristina Capusa

Reviewer's report:

Major compulsory revisions
1. Information about the used dose of cinacalcet is of great interest because it can influence the magnitude and the time to decrease serum iPTH and calcium, and consequently the discontinuation of therapy. The informative value of the manuscript would be significantly improved by adding this data. However, if there is no possibility to provide it, a clear statement about this lack of data should be added to the study’s limitation discussion.
2. The cause of cinacalcet discontinuation (indication from the physician or patient’s self choice) can not be known for sure as per the study design. So, the discussion about patients’ adherence (page 12-13, lines 280-289) seems rather speculative. A comment about this should be added.

Minor essential revisions
1. Some studied variables, especially the serum iPTH level, would be better characterized by median (instead of mean). Therefore, I suggest changing the Figure 1 and data from Table 1 accordingly.

Discretionary revisions

- 

Level of interest: An article whose findings are important to those with closely related research interests

Quality of written English: Acceptable

Statistical review: No, the manuscript does not need to be seen by a statistician.

Declaration of competing interests:

I have received speaker fees and financial support for attending scientific meetings from Amgen, Abbvie, Fresenius, Sanofi-Aventis, and Vifor Pharma.